secwatch / observer
8-K filed March 10, 2022, 6:59 PM ET ticker FULC CIK 0001680581
leadership confidence high sentiment neutral materiality 0.30

Fulcrum Therapeutics eliminates VP Finance role; appoints Gregory Tourangeau as principal accounting officer

Fulcrum Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Peter Thomson

Principal Accounting Officer
FULC · Fulcrum Therapeutics, Inc.
Effective
2022-03-11
Successor
Gregory Tourangeau
Filed
March 10, 2022, 6:59 PM ET
On March 4, 2022, Fulcrum Therapeutics, Inc. (“Fulcrum”) notified Mr. Peter Thomson of the elimination of the Vice President, Finance & Accounting position and, as a consequence, the termination of his role as Fulcrum’s principal accounting officer, effective as of March 11, 2022.
Appointed

Gregory Tourangeau

Principal Accounting Officer
FULC · Fulcrum Therapeutics, Inc.
Effective
2022-03-11
Filed
March 10, 2022, 6:59 PM ET
Fulcrum appointed Mr. Gregory Tourangeau, Fulcrum’s Controller, as principal accounting officer effective March 11, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Thomson was terminated as Principal Accounting Officer at Fulcrum Therapeutics, Inc..

Action
terminated
Role
Principal Accounting Officer
Exact text from the filing
On March 4, 2022, Fulcrum Therapeutics, Inc. (“Fulcrum”) notified Mr. Peter Thomson of the elimination of the Vice President, Finance & Accounting position and, as a consequence, the termination of his role as Fulcrum’s principal accounting officer, effective as of March 11, 2022.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Gregory Tourangeau was appointed as Principal Accounting Officer at Fulcrum Therapeutics, Inc..

Action
appointed
Role
Principal Accounting Officer
Exact text from the filing
Fulcrum appointed Mr. Gregory Tourangeau, Fulcrum’s Controller, as principal accounting officer effective March 11, 2022.
View on SEC.gov

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-22-072011
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.